Share-based Payment Arrangement, Expense of Pyxis Oncology, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Pyxis Oncology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Pyxis Oncology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,073,000, a 3.1% increase year-over-year.
  • Pyxis Oncology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,492,000, a 6.7% decline year-over-year.
  • Pyxis Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,945,000, a 24% decline from 2023.
  • Pyxis Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $16,946,000, a 7.5% increase from 2022.
  • Pyxis Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,764,000, a 147% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Pyxis Oncology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,492,000 $3,073,000 +$92,000 +3.1% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $12,400,000 $3,015,000 +$144,000 +5% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $12,256,000 $3,631,000 -$689,000 -16% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $12,945,000 $2,773,000 -$443,000 -14% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $13,388,000 $2,981,000 -$2,197,000 -42% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $15,585,000 $2,871,000 -$797,000 -22% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $16,382,000 $4,320,000 -$564,000 -12% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $16,946,000 $3,216,000 -$3,224,000 -50% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $20,170,000 $5,178,000 +$2,021,000 +64% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $18,149,000 $3,668,000 +$847,000 +30% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $17,302,000 $4,884,000 +$1,538,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $15,764,000 $6,440,000 +$3,372,000 +110% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $12,392,000 $3,157,000 +$2,850,000 +928% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $9,542,000 $2,821,000 +$2,268,000 +410% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $7,274,000 $3,346,000 +$902,000 +37% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $6,372,000 $3,068,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $307,000 +$295,000 +2458% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $553,000 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $2,444,000 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q3 2020 $12,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3

Pyxis Oncology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,945,000 -$4,001,000 -24% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $16,946,000 +$1,182,000 +7.5% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $15,764,000 +$9,392,000 +147% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $6,372,000 +$6,354,000 +35300% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $18,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.